Cancer Treatment Approaches

A groundbreaking study published in Nature (Jan 2025) significantly expanded our understanding of GBM-neural circuit interaction (Song lab at University of Pennsylvania School of Medicine). Sun et al. demonstrate that GBM integrates more extensively and rapidly into neural circuits than previously understood, making GBM not only a locally invasive tumor but also a systemic disease interconnected through local & distant neural networks. Notably, a novel therapeutic target was identified—cholinergic metabotropic receptor (CHRM3). Acetylcholine acts through CHRM3 on GBM cells to induce transcriptional reprogramming that promotes tumor invasion and malignancy. Consequently, blocking CHRM3 receptor function reduced cell motility and significantly improved survival in animal models. Overall, this work provides a transformative perspective on the neurobiology of GBM, setting the foundation for novel strategies targeting GBM's neural interaction.

Scientists have made one of the most startling and promising discoveries in brain cancer research. A new study shows that a simple combination of an antidepressant and a blood thinner forced glioblastoma cells into a state of lethal autophagy in mice. Autophagy is the process where cells break down and recycle their own components. In normal cells it is a survival mechanism. In cancer cells this controlled breakdown can become so extreme that the cells collapse and die. Researchers found that when these two drugs were paired together they pushed glioblastoma cells past their survival point and turned autophagy into a death trigger. Glioblastoma is one of the most aggressive and deadly forms of brain cancer and current treatments offer limited long term success. This discovery is gaining global attention because it uses already known drugs that could be repurposed faster than completely new medications. Scientists reported that the treated tumors shrank dramatically in mice as cancer cells began consuming themselves until they were no longer able to survive. Healthy cells were not harmed which makes this approach even more promising. Experts emphasize that although this success has been shown in mice human trials will be required to understand safety dosage and long term outcomes. Still this research opens a new pathway for developing treatments that attack cancer by turning its own survival system against itself. The idea that deadly tumors could be taught to self destruct is capturing worldwide interest. This breakthrough brings real hope and shows how innovative thinking can lead to powerful new strategies against one of the hardest cancers to treat.

UC San Diego may have cracked one of oncology’s hardest problems - treatment resistance. Scientists engineered a new antibody that targets integrin αvβ3, a protein found in aggressive cancers but absent in healthy tissue. → Activates macrophages (not NK cells) to kill tumor cells → Boosts iNOS and nitric oxide to trigger cancer cell death → Worked in both mouse models and patient-derived tumors That’s a new playbook: reprogram the tumor’s immune environment instead of fighting it. If clinical trials confirm this, we could be looking at a precision immunotherapy that turns tumors’ own defenses against them - and a real shot at taming resistance itself.

Tumor-infiltrating lymphocyte (TIL) therapy reached a milestone in 2024 with FDA approval of lifileucel for advanced melanoma. This comprehensive review by @Blanca Navarro Rodrigo reveals important patterns in how this immunotherapy works and where it's heading. Current Efficacy Patterns: - Melanoma: 34% response rate in PD-1 experienced patients, 44% in treatment-naive - NSCLC: 21.4% monotherapy response, 64.3% when combined with pembrolizumab - Variable results in other solid tumors (0-44% response rates) Key Predictive Biomarkers: Patient factors: Low LDH, limited tumor burden, fewer prior treatments Tumor characteristics: High mutational burden, strong antigen presentation machinery TIL product quality: Higher CD8+ T cell content, presence of tumor-reactive clones Post-treatment: Persistence of tumor-specific T cells in circulation Research shows three distinct exhaustion states in tumor-reactive T cells: - Progenitor exhausted (Tpex) - retain renewal capacity - Intermediate exhausted (Tex-int) - higher effector function - Terminal exhausted (Tex) - most dysfunctional - Success correlates with maintaining cells in less exhausted states during IL-2 expansion. Next-Generation Approaches: - CRISPR-modified TILs with PD-1 knockout - Engineered TILs expressing membrane-bound IL-15 or IL-7 - Neoantigen-selected TIL expansion protocols - Combination with checkpoint inhibitors and targeted therapies Key Challenges: Extending efficacy beyond melanoma requires better understanding of tumor microenvironment differences and resistance mechanisms in various cancer types. The field is moving toward precision approaches using multi-omic biomarkers to select optimal patients and customize treatment protocols for individual tumor characteristics.

Researchers have developed a breakthrough "molecular jackhammer" technique that uses near-infrared light to physically destroy cancer cells. This method utilizes specialized dye molecules, known as aminocyanines, which attach to the surface of malignant cells. When exposed to specific frequencies of near-infrared light, these molecules vibrate in a synchronized, high-speed motion—a trillion times per second. This intense mechanical vibration creates tiny tears in the protective cell membranes, causing the cancer cells to rupture and expire. In laboratory settings, this mechanical approach has achieved a 99 percent kill rate, offering a powerful new way to eliminate tumors without relying on traditional chemical interventions. A primary advantage of this "molecular jackhammer" is its ability to bypass the drug resistance that often renders chemotherapy and other pharmaceutical treatments ineffective. Because the destruction is purely mechanical rather than chemical, the cancer cells cannot develop biological defenses against the physical impact. Furthermore, near-infrared light possesses the unique ability to penetrate deep into human tissue without causing damage to healthy cells. This allows for a highly targeted, non-invasive treatment that focuses the destructive energy solely on the tumor site, minimizing the systemic side effects typically associated with toxic therapies. The successful application of these molecular motors represents a significant leap forward in the field of nanomedicine. By moving toward a "mechanical" oncology model, researchers are opening doors to treating cancers in sensitive areas of the body where surgery or high-dose radiation might be too risky. While this technology is currently in the experimental phase, its potential to provide a drug-free, highly efficient alternative to current standards of care is immense. As clinical trials move forward, this innovation could redefine the future of cancer treatment, making it safer and more precise for patients worldwide. #CancerResearch #Nanotechnology #MedicalInnovation

Targeting the RAS–MAPK pathway has transformed cancer therapy, yet pathway reactivation and dose-limiting toxicities continue to constrain the impact of RAS, RAF, and MEK inhibitors. In this News&Views article https://rdcu.be/eXjbA, I discuss the paper introducing IK-595 https://lnkd.in/e5cTs4EQ, a MEK–RAF molecular glue that stabilizes MEK in an inactive complex with RAF isoforms. This mechanism enables durable ERK pathway inhibition and anti-tumor activity across multiple RAS- or RAF-altered cancers, both as monotherapy and in combination. More broadly, this work highlights an emerging paradigm in kinase drug discovery, where stabilizing kinase complexes, not just inhibiting enzyme activity, may broaden therapeutic opportunities. #MAPK #RAS #RAF #MEK #MolecularGlue #Kinase #CancerResearch #TargetedTherapy #DrugDiscovery

This Nature article explores how radioligand therapies (RLTs) are reshaping cancer treatment by delivering targeted radiation directly to tumor cells, offering both therapeutic and diagnostic benefits. Unlike traditional radiotherapy, RLTs reduce damage to healthy tissue and are effective against metastatic disease. With established use in prostate cancer and neuroendocrine tumors—evidenced by blockbuster sales for a recent launch, the field is rapidly expanding, with 69 RLTs in clinical development as of early 2025. Advances in radioisotope selection, particularly the use of Lutetium-177 and emerging alpha emitters, aim to improve safety and precision. This growing momentum is driving significant investment and industry consolidation, positioning RLTs as a key frontier in oncology. #cancer #radioligandtherapy

🚀 Next-Gen Cancer Immunotherapy: CAR-NK & Unconventional CAR-T Cells 🔬 CGT is advancing rapidly! While CAR-T cells revolutionized blood cancer treatment, CAR-NK cells and unconventional CAR-T cells (γδ T, iNKT, MAIT) are emerging as next-gen therapies offering improved safety, scalability, and efficacy, particularly for solid tumors. 1️⃣ CAR-NK Cells: Safer, Scalable, & Off-the-Shelf Unlike CAR-T cells, which require patient-specific manufacturing and can cause severe toxicities, CAR-NK cells offer an off-the-shelf, allogeneic alternative with fewer side effects and easier scalability. 🧬 Why CAR-NK Cells? ✅ Lower Toxicity: CAR-T often causes CRS, ICANS, and GvHD, while CAR-NK cells show much lower toxicity. ✅ No GvHD Risk: HLA mismatch isn't a concern with NK cells, enabling universal application. ✅ Immediate Cytotoxicity: CAR-NK cells directly kill tumor cells without needing activation. ✅ Scalable Manufacturing: Produced from cord blood, iPSCs, or NK-92, allowing large-scale production. ✅ Proven efficacy in blood cancers: 73% response rate in CD19-CAR NK trials for B-cell malignancies. 🚨 Challenges & Solutions 🔁 Persistence? Enhancing persistence with IL-15, IL-21, and PD-1 blockade. 🦠 Solid Tumors? Overcoming TME barriers with new combinations of immune checkpoint inhibitors. 🔬 Active Trials: ✔️ CD19-CAR NK (NCT03056339) for blood cancers ✔️ HER2-CAR NK (NCT04319757) for solid tumors 2️⃣ Unconventional CAR-T Cells: Expanding the Immunotherapy Toolbox γδ T, iNKT, and MAIT cells offer unique advantages in tumor targeting, persistence, and immune evasion resistance. 🔥 γδ T Cells: MHC-Independent Tumor Recognition MHC-independent recognition allows γδ T cells to detect tumor stress ligands like MICA/B, enabling them to attack tumors escaping detection from conventional T cells. 📊 Clinical Progress ✔️ CAR-γδ T for glioblastoma (NCT04107142) ✔️ CAR-γδ T for lung cancer (NCT04735471) 🌍 iNKT Cells: Dual NK/T Function for Tumor Attack iNKT cells can bypass MHC limitations and stimulate broad immune responses. 🔬 Clinical Trials ✔️ CAR-iNKT for neuroblastoma (NCT03774654). 🌱 MAIT Cells: Targeting Mucosal Tumors MAIT cells are ideal for mucosal cancers (lung, liver, gut) due to their ability to recognize microbial-derived antigens. 🔬 Research ✔️ MAIT-based CAR therapies for liver cancer (preclinical) 📍 Links to the full texts 1️⃣ The clinical landscape of CAR NK cells: https://lnkd.in/dA7eV5FJ 2️⃣ The clinical landscape of CAR-engineered unconventional T cells: https://lnkd.in/dpbZza2G #CARTCells #CARNK #γδTCells #iNKTCells #MAITCells #CellTherapy #CancerResearch #Immunotherapy

Gliomas suck. They’re the most aggressive brain tumors out there, and even with surgery, chemo, and radiation, survival is often measured in months—not years. But here’s the wild part: cannabinoids are showing real promise against them. And not just by hitting CB1 or CB2, this new review highlights a whole web of ways cannabinoids mess with glioma cells EGFR signaling may get disrupted by cannabinoids and they are growth signals gliomas thrive on. Stress response (EIF2α & stress granules) - cannabinoids overload tumor cells with protein stress. Ferroptosis (GPX4 & ROS) - by changing iron metabolism, cannabinoids push cancer cells into an iron-driven oxidative death spiral. Autophagy - cannabinoids trigger cellular “self-recycle” pathways on glioma cells Mitochondria & ion channels (GPR55, TRPV1) are affected by cannabinoids - they break the energy supply lines and scramble calcium balance. This all means that tumor cells pushed toward cell death, while healthy cells are often left relatively untouched. We’re not there yet—most of this is preclinical—but the science is mounting. in fact the ARISTOCRAT trial (Phase II and ongoing; launched 2024) is testing nabiximols + TMZ (a chemotherapy) recurrent GBM. This is designed to provide the first robust evidence for cannabinoid in glioma treatment Javid FA, Belancic A, Kwok MK, Lam YW. Recent Advances in the Therapeutic Potential of Cannabinoids Against Gliomas: A Systematic Review (2022-2025). Pharmacol Res Perspect. 2025 Aug;13(4):e70160. doi: 10.1002/prp2.70160. PMID: 40781861; PMCID: PMC12334796.

GBM can be immunologically "cold" not because T cells are absent but because they are present yet functionally restrained. So therapeutic strategy slightly shifts from simply "infiltrating the cold" to reactivating pre-existing intratumoral T cells. This new paper reports an oncolytic virus trial that provides the spatial evidence: -A single treatment leads to local expansion of pre-existing tumor-infiltrating T cells; -Granzyme B+ T cells positioned in close proximity to apoptotic tumor cells; -Shorter T cell-tumor cell distances correlate with longer PFS. Viral remnants are confined to necrotic regions. T cells are not; They infiltrate live tumor, persist and remain engaged. The dominant signal is not de novo priming but expansion of already recruited inert clones. OVs here function as in situ immune reactivators, converting a quiescent infiltrate into sustained, spatially engaged cytotoxicity. This work also reinforces that functional spatial engagement may be a more meaningful response biomarker axis rather than bulk immune signatures alone. #GBM #OncolyticVirus #TME #SpatialTranscriptomics #CancerImmunotherapy #TranslationalScience #Oncology #Glioblastoma https://lnkd.in/dWR3TCQQ